Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008–2011
Abstract Long term control of rubella and congenital rubella syndrome relies on high population-level immunity against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be screened so that susceptible new mothers can be offered vaccination for rubella before...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2017-05, Vol.35 (23), p.3050-3055 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3055 |
|---|---|
| container_issue | 23 |
| container_start_page | 3050 |
| container_title | Vaccine |
| container_volume | 35 |
| creator | Gilbert, Nicolas L Rotondo, Jenny Shapiro, Janna Sherrard, Lindsey Fraser, William D Ward, Brian J |
| description | Abstract Long term control of rubella and congenital rubella syndrome relies on high population-level immunity against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be screened so that susceptible new mothers can be offered vaccination for rubella before discharge. This study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and to identify associated socio-economic and demographic factors. Biobanked plasma samples were obtained from the Maternal-Infant Research on Environmental Chemicals (MIREC) study, in which pregnant women were recruited between 2008 and 2011. Socio-demographic characteristics and obstetric histories were collected. Second trimester plasma samples (n = 1,752) were tested for rubella-specific IgG using an in-house enzyme-linked immunosorbent assay. The percentage of women with IgG titers |
| doi_str_mv | 10.1016/j.vaccine.2017.04.057 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1894521485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X17305492</els_id><sourcerecordid>1894521485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561t-d952067a5383a236148118f4af871bad1702686179c075be072c1f687a5fcfb03</originalsourceid><addsrcrecordid>eNqFkk2O1DAQhS0EYnoGjgCKxIYFCVVOnLg3INTiTxqJxYDEznKcCrhJ7MZOGvWO3RyAG3ISHHUzSLNhZcv-3nOVXzH2CKFAwPr5tthrY6yjggM2BVQFiOYOW6FsypwLlHfZCnhd5RXC5zN2HuMWAESJ6_vsjMuqRqjrFbu-ouB3gfZ6IGco830W5paGQWfaTbb1naWYtl3W0URhtC4dxwWLczS0S4gd7HTIJn8jtC7TmfFffZgWMLl_WVTZDz-SW2432ulOP8s4gPz981dqAB-we70eIj08rRfs05vXHzfv8ssPb99vXl3mRtQ45d1acKgbLUpZal7WWElE2Ve6lw22usMm9SxrbNYGGtESNNxgX8uk6E3fQnnBnh59d8F_nylOarSpj1S2Iz9HhXJdCZ5sRUKf3EK3fg4uVbdQEqGseJkocaRM8DEG6tUu2FGHg0JQS1Jqq05JqSUpBZVKSSXd45P73I7U3aj-RpOAl0eA0nfsLQUVjV0y6mwgM6nO2_8-8eKWgxmss0YP3-hA8V83KnIF6moZl2VasClBVGte_gESlbvU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1898103423</pqid></control><display><type>article</type><title>Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008–2011</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Gilbert, Nicolas L ; Rotondo, Jenny ; Shapiro, Janna ; Sherrard, Lindsey ; Fraser, William D ; Ward, Brian J</creator><creatorcontrib>Gilbert, Nicolas L ; Rotondo, Jenny ; Shapiro, Janna ; Sherrard, Lindsey ; Fraser, William D ; Ward, Brian J</creatorcontrib><description>Abstract Long term control of rubella and congenital rubella syndrome relies on high population-level immunity against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be screened so that susceptible new mothers can be offered vaccination for rubella before discharge. This study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and to identify associated socio-economic and demographic factors. Biobanked plasma samples were obtained from the Maternal-Infant Research on Environmental Chemicals (MIREC) study, in which pregnant women were recruited between 2008 and 2011. Socio-demographic characteristics and obstetric histories were collected. Second trimester plasma samples (n = 1,752) were tested for rubella-specific IgG using an in-house enzyme-linked immunosorbent assay. The percentage of women with IgG titers <5 IU/mL, 5–10 IU/mL, and ≥10 IU/mL were 2.3%, 10.1%, and 87.6%, respectively. Rates of seronegativity, defined as <5 IU/mL, were 3.1% in women who had no previous live birth and 1.6% in women who had given birth previously. Among the latter group, seronegativity was higher in women with high school education or less (adjusted OR (aOR) 5.93, 95% CI 2.08–16.96) or with a college or trade school diploma (aOR 3.82, 95% CI 1.45–10.12), compared to university graduates, and those born outside Canada (aOR 2.60, 95% CI 1.07–6.31). In conclusion, a large majority of pregnant women were found to be immune to rubella. Further research is needed to understand inequalities in vaccine uptake or access, and more effort is needed to promote catch-up measles-mumps-rubella vaccination among socioeconomically disadvantaged and immigrant women of childbearing age.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2017.04.057</identifier><identifier>PMID: 28461066</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Adults ; Age ; Allergy and Immunology ; Anomalies ; Antibodies ; Antibodies, Viral - blood ; Arthralgia ; Arthritis ; Assaying ; Attenuation ; Autism ; Blocking ; Brain ; Brain injury ; Canada ; Canada - epidemiology ; Children ; Cohort Studies ; Collection ; Congenital defects ; Congenital rubella ; Deafness ; Defects ; Dilution ; Disease Susceptibility ; Disease transmission ; Documents ; Educational Status ; Encephalomyelitis ; Environmental research ; Enzyme-Linked Immunosorbent Assay ; Exposure ; Eye ; Female ; Fever ; Health risk assessment ; Health risks ; Heart ; Hum ; Humans ; Immunoglobulin G ; Immunoglobulin G - blood ; Immunoglobulins ; Incidence ; Meningoencephalitis ; Middle Aged ; Pharmacology ; Postpartum vaccination ; Pregnancy ; Pregnancy Complications, Infectious - immunology ; Pregnancy Complications, Infectious - prevention & control ; Pregnancy Complications, Infectious - virology ; Prenatal experience ; Public health ; Ribonucleic acid ; Risk ; RNA ; Rubella ; Rubella - epidemiology ; Rubella - immunology ; Rubella - virology ; Rubella Syndrome, Congenital - prevention & control ; Seroconversion ; Seroepidemiologic Studies ; Statistical analysis ; Temperature effects ; Vaccination ; Vaccines ; Viruses ; Womens health ; Young Adult</subject><ispartof>Vaccine, 2017-05, Vol.35 (23), p.3050-3055</ispartof><rights>2017</rights><rights>Crown Copyright © 2017. Published by Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited May 25, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c561t-d952067a5383a236148118f4af871bad1702686179c075be072c1f687a5fcfb03</citedby><cites>FETCH-LOGICAL-c561t-d952067a5383a236148118f4af871bad1702686179c075be072c1f687a5fcfb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1898103423?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28461066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gilbert, Nicolas L</creatorcontrib><creatorcontrib>Rotondo, Jenny</creatorcontrib><creatorcontrib>Shapiro, Janna</creatorcontrib><creatorcontrib>Sherrard, Lindsey</creatorcontrib><creatorcontrib>Fraser, William D</creatorcontrib><creatorcontrib>Ward, Brian J</creatorcontrib><title>Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008–2011</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Long term control of rubella and congenital rubella syndrome relies on high population-level immunity against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be screened so that susceptible new mothers can be offered vaccination for rubella before discharge. This study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and to identify associated socio-economic and demographic factors. Biobanked plasma samples were obtained from the Maternal-Infant Research on Environmental Chemicals (MIREC) study, in which pregnant women were recruited between 2008 and 2011. Socio-demographic characteristics and obstetric histories were collected. Second trimester plasma samples (n = 1,752) were tested for rubella-specific IgG using an in-house enzyme-linked immunosorbent assay. The percentage of women with IgG titers <5 IU/mL, 5–10 IU/mL, and ≥10 IU/mL were 2.3%, 10.1%, and 87.6%, respectively. Rates of seronegativity, defined as <5 IU/mL, were 3.1% in women who had no previous live birth and 1.6% in women who had given birth previously. Among the latter group, seronegativity was higher in women with high school education or less (adjusted OR (aOR) 5.93, 95% CI 2.08–16.96) or with a college or trade school diploma (aOR 3.82, 95% CI 1.45–10.12), compared to university graduates, and those born outside Canada (aOR 2.60, 95% CI 1.07–6.31). In conclusion, a large majority of pregnant women were found to be immune to rubella. Further research is needed to understand inequalities in vaccine uptake or access, and more effort is needed to promote catch-up measles-mumps-rubella vaccination among socioeconomically disadvantaged and immigrant women of childbearing age.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Anomalies</subject><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Arthralgia</subject><subject>Arthritis</subject><subject>Assaying</subject><subject>Attenuation</subject><subject>Autism</subject><subject>Blocking</subject><subject>Brain</subject><subject>Brain injury</subject><subject>Canada</subject><subject>Canada - epidemiology</subject><subject>Children</subject><subject>Cohort Studies</subject><subject>Collection</subject><subject>Congenital defects</subject><subject>Congenital rubella</subject><subject>Deafness</subject><subject>Defects</subject><subject>Dilution</subject><subject>Disease Susceptibility</subject><subject>Disease transmission</subject><subject>Documents</subject><subject>Educational Status</subject><subject>Encephalomyelitis</subject><subject>Environmental research</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Exposure</subject><subject>Eye</subject><subject>Female</subject><subject>Fever</subject><subject>Health risk assessment</subject><subject>Health risks</subject><subject>Heart</subject><subject>Hum</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulins</subject><subject>Incidence</subject><subject>Meningoencephalitis</subject><subject>Middle Aged</subject><subject>Pharmacology</subject><subject>Postpartum vaccination</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - immunology</subject><subject>Pregnancy Complications, Infectious - prevention & control</subject><subject>Pregnancy Complications, Infectious - virology</subject><subject>Prenatal experience</subject><subject>Public health</subject><subject>Ribonucleic acid</subject><subject>Risk</subject><subject>RNA</subject><subject>Rubella</subject><subject>Rubella - epidemiology</subject><subject>Rubella - immunology</subject><subject>Rubella - virology</subject><subject>Rubella Syndrome, Congenital - prevention & control</subject><subject>Seroconversion</subject><subject>Seroepidemiologic Studies</subject><subject>Statistical analysis</subject><subject>Temperature effects</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Viruses</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk2O1DAQhS0EYnoGjgCKxIYFCVVOnLg3INTiTxqJxYDEznKcCrhJ7MZOGvWO3RyAG3ISHHUzSLNhZcv-3nOVXzH2CKFAwPr5tthrY6yjggM2BVQFiOYOW6FsypwLlHfZCnhd5RXC5zN2HuMWAESJ6_vsjMuqRqjrFbu-ouB3gfZ6IGco830W5paGQWfaTbb1naWYtl3W0URhtC4dxwWLczS0S4gd7HTIJn8jtC7TmfFffZgWMLl_WVTZDz-SW2432ulOP8s4gPz981dqAB-we70eIj08rRfs05vXHzfv8ssPb99vXl3mRtQ45d1acKgbLUpZal7WWElE2Ve6lw22usMm9SxrbNYGGtESNNxgX8uk6E3fQnnBnh59d8F_nylOarSpj1S2Iz9HhXJdCZ5sRUKf3EK3fg4uVbdQEqGseJkocaRM8DEG6tUu2FGHg0JQS1Jqq05JqSUpBZVKSSXd45P73I7U3aj-RpOAl0eA0nfsLQUVjV0y6mwgM6nO2_8-8eKWgxmss0YP3-hA8V83KnIF6moZl2VasClBVGte_gESlbvU</recordid><startdate>20170525</startdate><enddate>20170525</enddate><creator>Gilbert, Nicolas L</creator><creator>Rotondo, Jenny</creator><creator>Shapiro, Janna</creator><creator>Sherrard, Lindsey</creator><creator>Fraser, William D</creator><creator>Ward, Brian J</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20170525</creationdate><title>Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008–2011</title><author>Gilbert, Nicolas L ; Rotondo, Jenny ; Shapiro, Janna ; Sherrard, Lindsey ; Fraser, William D ; Ward, Brian J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561t-d952067a5383a236148118f4af871bad1702686179c075be072c1f687a5fcfb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Anomalies</topic><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Arthralgia</topic><topic>Arthritis</topic><topic>Assaying</topic><topic>Attenuation</topic><topic>Autism</topic><topic>Blocking</topic><topic>Brain</topic><topic>Brain injury</topic><topic>Canada</topic><topic>Canada - epidemiology</topic><topic>Children</topic><topic>Cohort Studies</topic><topic>Collection</topic><topic>Congenital defects</topic><topic>Congenital rubella</topic><topic>Deafness</topic><topic>Defects</topic><topic>Dilution</topic><topic>Disease Susceptibility</topic><topic>Disease transmission</topic><topic>Documents</topic><topic>Educational Status</topic><topic>Encephalomyelitis</topic><topic>Environmental research</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Exposure</topic><topic>Eye</topic><topic>Female</topic><topic>Fever</topic><topic>Health risk assessment</topic><topic>Health risks</topic><topic>Heart</topic><topic>Hum</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulins</topic><topic>Incidence</topic><topic>Meningoencephalitis</topic><topic>Middle Aged</topic><topic>Pharmacology</topic><topic>Postpartum vaccination</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - immunology</topic><topic>Pregnancy Complications, Infectious - prevention & control</topic><topic>Pregnancy Complications, Infectious - virology</topic><topic>Prenatal experience</topic><topic>Public health</topic><topic>Ribonucleic acid</topic><topic>Risk</topic><topic>RNA</topic><topic>Rubella</topic><topic>Rubella - epidemiology</topic><topic>Rubella - immunology</topic><topic>Rubella - virology</topic><topic>Rubella Syndrome, Congenital - prevention & control</topic><topic>Seroconversion</topic><topic>Seroepidemiologic Studies</topic><topic>Statistical analysis</topic><topic>Temperature effects</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Viruses</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gilbert, Nicolas L</creatorcontrib><creatorcontrib>Rotondo, Jenny</creatorcontrib><creatorcontrib>Shapiro, Janna</creatorcontrib><creatorcontrib>Sherrard, Lindsey</creatorcontrib><creatorcontrib>Fraser, William D</creatorcontrib><creatorcontrib>Ward, Brian J</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gilbert, Nicolas L</au><au>Rotondo, Jenny</au><au>Shapiro, Janna</au><au>Sherrard, Lindsey</au><au>Fraser, William D</au><au>Ward, Brian J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008–2011</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2017-05-25</date><risdate>2017</risdate><volume>35</volume><issue>23</issue><spage>3050</spage><epage>3055</epage><pages>3050-3055</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract Long term control of rubella and congenital rubella syndrome relies on high population-level immunity against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be screened so that susceptible new mothers can be offered vaccination for rubella before discharge. This study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and to identify associated socio-economic and demographic factors. Biobanked plasma samples were obtained from the Maternal-Infant Research on Environmental Chemicals (MIREC) study, in which pregnant women were recruited between 2008 and 2011. Socio-demographic characteristics and obstetric histories were collected. Second trimester plasma samples (n = 1,752) were tested for rubella-specific IgG using an in-house enzyme-linked immunosorbent assay. The percentage of women with IgG titers <5 IU/mL, 5–10 IU/mL, and ≥10 IU/mL were 2.3%, 10.1%, and 87.6%, respectively. Rates of seronegativity, defined as <5 IU/mL, were 3.1% in women who had no previous live birth and 1.6% in women who had given birth previously. Among the latter group, seronegativity was higher in women with high school education or less (adjusted OR (aOR) 5.93, 95% CI 2.08–16.96) or with a college or trade school diploma (aOR 3.82, 95% CI 1.45–10.12), compared to university graduates, and those born outside Canada (aOR 2.60, 95% CI 1.07–6.31). In conclusion, a large majority of pregnant women were found to be immune to rubella. Further research is needed to understand inequalities in vaccine uptake or access, and more effort is needed to promote catch-up measles-mumps-rubella vaccination among socioeconomically disadvantaged and immigrant women of childbearing age.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>28461066</pmid><doi>10.1016/j.vaccine.2017.04.057</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2017-05, Vol.35 (23), p.3050-3055 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1894521485 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Adolescent Adult Adults Age Allergy and Immunology Anomalies Antibodies Antibodies, Viral - blood Arthralgia Arthritis Assaying Attenuation Autism Blocking Brain Brain injury Canada Canada - epidemiology Children Cohort Studies Collection Congenital defects Congenital rubella Deafness Defects Dilution Disease Susceptibility Disease transmission Documents Educational Status Encephalomyelitis Environmental research Enzyme-Linked Immunosorbent Assay Exposure Eye Female Fever Health risk assessment Health risks Heart Hum Humans Immunoglobulin G Immunoglobulin G - blood Immunoglobulins Incidence Meningoencephalitis Middle Aged Pharmacology Postpartum vaccination Pregnancy Pregnancy Complications, Infectious - immunology Pregnancy Complications, Infectious - prevention & control Pregnancy Complications, Infectious - virology Prenatal experience Public health Ribonucleic acid Risk RNA Rubella Rubella - epidemiology Rubella - immunology Rubella - virology Rubella Syndrome, Congenital - prevention & control Seroconversion Seroepidemiologic Studies Statistical analysis Temperature effects Vaccination Vaccines Viruses Womens health Young Adult |
| title | Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008–2011 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A50%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Seroprevalence%20of%20rubella%20antibodies%20and%20determinants%20of%20susceptibility%20to%20rubella%20in%20a%20cohort%20of%20pregnant%20women%20in%20Canada,%202008%E2%80%932011&rft.jtitle=Vaccine&rft.au=Gilbert,%20Nicolas%20L&rft.date=2017-05-25&rft.volume=35&rft.issue=23&rft.spage=3050&rft.epage=3055&rft.pages=3050-3055&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2017.04.057&rft_dat=%3Cproquest_cross%3E1894521485%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1898103423&rft_id=info:pmid/28461066&rft_els_id=S0264410X17305492&rfr_iscdi=true |